@article {Font1552, author = {Josep Font and Manuel Ramos-Casals and Gloria de la Red and Adolf Pou and Arnau Casanova and Mario Garc{\'\i}a-Carrasco and Ricard Cervera and Jos{\'e} A Molina and Josep Valls and Albert Bov{\'e} and Miguel Ingelmo and Francesc Graus}, title = {Pure sensory neuropathy in primary Sj{\"o}gren{\textquoteright}s syndrome. Longterm prospective followup and review of the literature.}, volume = {30}, number = {7}, pages = {1552--1557}, year = {2003}, publisher = {The Journal of Rheumatology}, abstract = {OBJECTIVE: To study the clinical course, response to therapy, and longterm outcome of pure sensory neuropathy (PSN) in a series of patients with primary Sj{\"o}gren{\textquoteright}s syndrome (SS) followed prospectively in our referral centers. METHODS: We studied 15 patients (13 women, 2 men) with primary SS and PSN. All patients fulfilled 4 or more of the European diagnostic criteria. RESULTS: At diagnosis of PSN, clinical manifestations included numbness and paresthesias (11 patients), trigeminal neuropathy (6 patients), and Adie{\textquoteright}s pupil syndrome (4 patients). In 7 patients, PSN was diagnosed prior to SS, in 5 the diagnoses were made simultaneously, and in the remaining 3 patients PSN was diagnosed after the appearance of SS symptomatology. The mean duration of the prospective PSN followup was 10 years (range 1-20). The progression of PSN was acute in 1 patient (producing severe dysfunction in less than 1 month), subacute in 3 patients, and in the remaining 11, the symptoms progressed slowly over the ensuing years to other extremities. Patients were treated with corticosteroids (n = 13), cyclophosphamide (n = 4), and intravenous immunoglobulins (n = 1), and 2 patients received no treatment. In spite of treatment, most patients showed an indolent and insidious longterm PSN course. CONCLUSION: We found 3 differentiated clinical courses of the PSN in patients with primary SS: subacute progression in less than 1 month (7\%), late acceleration of PSN 2-4 years after an initial indolent onset (20\%), and a very longterm insidious, chronic evolution (73\%). Prospective analysis of the longterm course of PSN shows a chronic and insidious evolution in most patients with PSN and SS, with a poor response to treatment, although stabilization of symptomatology for long periods is often observed.}, issn = {0315-162X}, URL = {https://www.jrheum.org/content/30/7/1552}, eprint = {https://www.jrheum.org/content/30/7/1552.full.pdf}, journal = {The Journal of Rheumatology} }